Blar i NTNU Open på forfatter "Aas, Turid"
-
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein (Peer reviewed; Journal article, 2015)Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on single gene mutations, we hypothesize chemoresistance to be due to inactivation of key pathways affecting cellular mechanisms such as ... -
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer
Yndestad, Synnøve; Engebrethsen, Christina; Herencia-Ropero, A.; Nikolaienko, Oleksii; Vintermyr, Olav Karsten; Lillestøl, Reidun Kristine; Minsaas, Laura; Leirvaag, Beryl; Iversen, Gjertrud Titlestad; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Aase, Hildegunn Siv; Aas, Turid; Gudlaugsson, Einar; Llop-Guevara, Alba; Serra, Violeta; Janssen, Emiel; Lønning, Per Eystein; Knappskog, Stian; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2023)Purpose Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to ... -
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2020)Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ... -
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjøsne, Hans Erikssønn; Nysted, Arne; Lillehaug, Johan R.; Lønning, Per Eystein (Journal article; Peer reviewed, 2011) -
The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway
Opsahl, Else Marie; Akslen, Lars A.; Schlichting, Ellen; Aas, Turid; Brauckhoff, Katrin; Hagen, Anne Irene; Rosenlund, Alf Friman; Sigstad, Eva; Kotanska-Grøholt, Krystyna; Jørgensen, Lars Hilmar; Bjøro, Trine (Peer reviewed; Journal article, 2019) -
Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study
Opsahl, Else Marie; Akslen, Lars Andreas; Schlichting, Ellen; Aas, Turid; Brauckhoff, Katrin; Hagen, Anne Irene; Rosenlund, Alf Frimann; Sigstad, Eva; Grøholt, Krystyna K.; Mæhle, Lovise Olaug; Engebretsen, Lars Fredri; Jørgensen, Lars H.; Varhaug, Jan Erik; Bjøro, Trine (Peer reviewed; Journal article, 2018)Background: Medullary thyroid carcinoma (MTC) is rare. Nationwide population-based studies are important to evaluate its clinical course. Objectives: To describe all patients with MTC in Norway during 1994–2016 and compare ...